Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Dexamethasone × Dermatologic × Clear all

Phase

Status

Completed 7 Withdrawn 1 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 37 Lymphoid 9 Other hematologic neoplasm 6 CNS 3 Thoracic 2 Genitourinary 2 Sarcoma 1 Other 1 Gastrointestinal 1 Dermatologic 1

Conditions

Interventions

Nivolumab 16 Ipilimumab 15 pembrolizumab 11 Cyclophosphamide 11 trametinib 9 Radiotherapy 8 dabrafenib 6 sargramostim 5 Interleukin-2 5 Fluorouracil 5 130-nm albumin-bound paclitaxel 5 aldesleukin 4 Vemurafenib 4 Radiosurgery 4 Peripheral Blood Stem Cell Transplantation 4 Melphalan 4 fludarabine phosphate 3 fludarabine 3 durvalumab 3 avelumab 3 Specimen Handling 3 Magnetic Resonance Spectroscopy 3 Leucovorin 3 Granulocyte-Macrophage Colony-Stimulating Factor 3 Cytarabine 3 Capecitabine 3 Biopsy 3 Bevacizumab 3 encorafenib 2 binimetinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02862145 2016-09-27

MRX34-102

Mirna Therapeutics, Inc.

Phase 1/2 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡